Dec. 5. 2017 8:51AM

RECEIVED 12/05/2017 08:49AM No. 2421 P. 18586

	سين التراك					
ORANGL REGIONAL MEDICA Physician Order For	AL CENTER in	Hos dags	Lan, year	Yeghiche 40		
		· POR	-11/17/19	40		
DO NOT USE ABBREVIATIONS:			·	,		
	QD μg					
IU SC SQ SL	QOD		fidient Laber			
OUTPATIENT DARBEPOETIN	<u>Aranesp®)</u> Er	<u>/thropoetic Stimul</u>	ating Agent (E	A) Order Form		
			·			
Initial Hemoglobin (Hgb)/Hematocrit Current Hgb: Hct;	(Hct) Date/level		\	: kg		
DIAGNOSIS (Check one):	_ _			·		
Chemotherapy induced anemic	a					
Hemoglobin (Hgb) / Hematocrit ((Hct) must be < 1	3 g/dí and < 30%				
i	nca/ka/week		•			
On week 4 doses may be increa By week 8 discontinue treatment	sed by 25% if Hg	0/Hct rise is < 1/3.				
		no is documented				
 End Stage Renal Disease (ESR 	D) on dialysis	11	a A - ne	-1. +m		
A Chronic Kidney Disease (CRD)	not on dialys	sis H7	000	>, 118mm		
 For ohronic kidney disease creat 	inine > 3 and CrO	i < 60 m L/min	H-Gr	> 1180am		
Monitor to ensure transferring sa	furation > 20% ar	id/or serum ferritin > 10	00 ng/mL	•		
□ HIV/AIDS anemia Induced by z	idovudine or o	ther nucleosida rev	erse transcriptes	se inhibitors		
Approla related to envelope	-4tl	/B.475.45\				
☐ Anemia related to myelodyspia Bone marrow biopsy < 5% blasts	stic synorome	(MDS) excluding A	ML and CML			
Erythropoietin level 100 or less			,			
After Z months of treatment cons	ider discontinuing	If there is no significan	t increase in Hgb/H	ct and/or		
decreased transfusions			-			
□ Treatment of anemia of selecte	d chronic diac					
Rheumatoid arthritis, systemic lu	ous erythematos:	soco 6. Inflammatory bowel	Mice sesses			
hepatitis C undergoing treatment	, , , , , , , , , , , , , , , , , , , ,	of an entitle coly botton	albéraca, dilo			
Initial Hab/Hat must be < 10 e/dl =		. 8				
Initial Hgb/Hct must be < 10 g/dl at titrate dose of darbepoetin to main	tain a format U	all uses other than shiof 10,12 aidi oos	Chemotherapy in	iduced anemia		
timed dose adjustment,	rem a reidet Ui	ybor ro-iz gydrand	1 mc(or 30-36%	by abbrobuste		
Date of last ESA agent:	Do not gi	ve Darbepoetin mo	re frequently tha	n once weekly		
			-			
Drug	Dose (mcg)	Route	Frequency	RN/Time		
Don't an a 44 (4	-d-since	, Ba SubQ	every			
Darbepoetin (Aranesp®)	4 omg	ˈ□ IV	week			
	'		ween	<u> </u>		
Print Last Name RAMASWAM	19 Print	_ast Name:				
Physician Signature		Nurse Signature:Date:				
Date 6 15 18 Time: 100 7	RBV	RBV INITTime; Faxed D Time Faxed				

ORANGE ME REGIONAL

Informed Consent for Infusion Contor Treatment

_	85886
	PATIENT
L	HOSDAGHIAM
	DUB 11/12/1940

					•		YEGH
						Du B	4 EGH 11/12
heroby give my consent and authorize: D	or Ripo	MAS	wamy	and i	hose who he/s		
ssociates or assistants and Orange Region				in suff to p	erform the foll	omjing ng inga ngsib	Tiele Bâ
resument upon: Hos da gh	10 M	Ye_	ahich	<u>.</u>	_ ^		
(Patient	a namo);	,	<i>y</i>			· · · · · · · · · · · · · · · · · · ·	
Describe the treatment in both clinical and	i laymen's	ierms 1	io Actonyms	or Abbrevia	йода):	,	
/ a/ fa A	,					·	
as malin, my	t resp	<u>_9</u> v	but		<u>.</u> .	<u></u>	
·	<u>a</u>		<u> </u>		_		
Since and the delice and the second		/					 -
give permission with full knowledge and t	omografie	My Merc	di, i ungcisia Sta de sessita	oo wat med	cine is not an	STEEL SOLUTION	and that
ere is the possibility that the treatment me	ay mot mayo	1120 DOM:	XIII OL LOSVITA	intended, I	am also awaro	that there ar	e always
X8 slic-craff Ccts to title and upprin associti	roci Kerterat	וו ומונאי או	16. 1140 of med	ication, and	trontments wit.		adverso.
pusequences not ordinarily anticipated in	edvance, b	ar i Bino	bis pormissio	n with full a	ssent nevertite	C88.	
	- :		-				
	1	- :					
y signing below, I confirm that I fully un	derstand th	a inform	stion provided	l to mo, my (juestions bave	bеец апа <mark></mark> wег	ed, and l
ve my consent to the treatment(s) appoin	co anove		•			,	, unu -,
•							
	ļ. '	-			••		٨M
ation/Health Care Agen/Surrogate/Guardien Sign	(Sign)	(Printed	N	—- —		· _/_/	PM
		(v retrick)	THE ME	(Falley)	niship to Patient)	(Date)	-" (Time)
	40-	•					
	7.1						ΛM
Witness Signatura)	_	(T)	d Name)	··-·		_[. РМ
H UICOD DYELICIALA		(tante	or Legans)			(Date)	(Time)
	· , ·						
			•				,
Mark this box if telephone consent	₽.,	п	National Control	. 141	•		
AMERICANS COX II refebuore consent	W_{1}	D.	amer mia dox	it interprete	r was involved	[,	
	. j, +						
	10.7	_		•			
itave discussed the antire and purpose a	od the regal	omably fo	resceablé risk	deted for a	is of the treatur		,
TINGUE TO A TOUR DESCRIPTION OF THE PROPERTY O	* MD *** WILL HID		arki nenenia i	of the alterna	Mver and I on	residella la la	rottier[Acs*
r the patient's legal representative who a	igued aboy	o unders	lands them,			T SELIENCE IN	at two buriets
	1						
\wedge	رون ا	. .				,	•
1		<i>/</i> ~	•		· Alic	1,0/	<u> </u>
	-		<u>' </u>		" O IIS	113 /	2.804
Signature of Physician/Appropriately Cre	edentialed :	Practition	or Providing	Explanation	6/15	<u> </u>	
	', .ī	•	٠, ٣٠	*	, Da	tc_ / 7	ImE:
	- :					· / ·	
•	· , , , , ,	,				1,	
•				** *			
	;, ⁻		•		•		
	1	•	; -			•	

Risk Management/nam/August 2012

No. 2280

Page 1 of 1